Dermira (DERM) Earns Daily Media Sentiment Score of 0.21

News coverage about Dermira (NASDAQ:DERM) has trended somewhat positive on Saturday, according to Accern Sentiment. The research firm identifies positive and negative news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Dermira earned a news sentiment score of 0.21 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.3388080418006 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Several equities research analysts recently commented on DERM shares. Leerink Swann reissued an “outperform” rating and set a $41.00 price objective (down previously from $47.00) on shares of Dermira in a research note on Tuesday, November 7th. Guggenheim started coverage on shares of Dermira in a research note on Tuesday, December 5th. They set a “buy” rating on the stock. Mizuho dropped their price objective on shares of Dermira from $43.00 to $39.00 and set a “buy” rating on the stock in a research note on Tuesday, December 12th. Needham & Company LLC reissued a “buy” rating and set a $43.00 price objective (down previously from $46.00) on shares of Dermira in a research note on Tuesday, November 7th. Finally, BidaskClub downgraded shares of Dermira from a “buy” rating to a “hold” rating in a research note on Tuesday, January 9th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $42.17.

Dermira (DERM) traded down $0.76 on Friday, hitting $27.49. 747,017 shares of the stock traded hands, compared to its average volume of 635,992. The company has a debt-to-equity ratio of 1.40, a current ratio of 4.68 and a quick ratio of 4.68. Dermira has a 1 year low of $21.35 and a 1 year high of $38.75. The stock has a market capitalization of $1,177.29, a PE ratio of -4.41 and a beta of 0.75.

In other Dermira news, insider Eugene A. Bauer sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $27.34, for a total transaction of $82,020.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Christopher M. Griffith sold 18,458 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $27.05, for a total transaction of $499,288.90. The disclosure for this sale can be found here. Insiders have sold 34,258 shares of company stock valued at $935,153 over the last three months. 13.30% of the stock is owned by corporate insiders.

WARNING: This piece of content was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://stocknewstimes.com/2018/02/17/dermira-derm-getting-somewhat-positive-press-coverage-study-finds.html.

Dermira Company Profile

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Insider Buying and Selling by Quarter for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply